AIM ImmunoTech Inc. vs. Halozyme Therapeutics, Inc.
AIM ImmunoTech Inc. (AIM) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AIM | HALO | |
|---|---|---|
| Market Cap | $6.69 million | $11.20 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | — | $413.60 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| AIM | HALO | |
|---|---|---|
| P/E Ratio | — | 28.76 |
| Price / Book | 0.57 | 78.01 |
| Price / Sales | — | 6.73 |
AIM leads on 1 of 1 valuation factors.
Profitability
| AIM | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | — | 288.13% |
AIM and HALO split the profitability factors evenly.
Risk & Sentiment
| AIM | HALO | |
|---|---|---|
| Short Interest | 0.32% | 9.79% |
AIM leads on 1 of 1 risk & sentiment factors.
Dig deeper: AIM overview, AIM financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.